NCT05619367|Unknown
A Compassionate Use (CU) Program of Odronextamab
1 other identifier
R1979-Odronextamab
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredNov 2022
Brief Summary
Provide compassionate use of odronextamab
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 8, 2022
Completed8 days until next milestone
First Posted
Study publicly available on registry
November 16, 2022
CompletedLast Updated
December 23, 2025
Status Verified
December 1, 2025
First QC Date
November 8, 2022
Last Update Submit
December 22, 2025
Conditions
Interventions
OdronextamabDRUG
Also known as: REGN1979
Sponsors & Collaborators
MeSH Terms
Conditions
RecurrenceLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell
Condition Hierarchy (Ancestors)
Disease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases
Central Study Contacts
Requests for compassionate use must be initiated by a treating physician Physicians should contact
CONTACT
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 8, 2022
First Posted
November 16, 2022
Last Updated
December 23, 2025
Record last verified: 2025-12